Vitamin D and breast cancer

Theresa Shao, Paula Klein, Michael L Grossbard, Theresa Shao, Paula Klein, Michael L Grossbard

Abstract

In addition to its role in calcium homeostasis and bone health, vitamin D has also been reported to have anticancer activities against many cancer types, including breast cancer. The discovery that breast epithelial cells possess the same enzymatic system as the kidney, allowing local manufacture of active vitamin D from circulating precursors, makes the effect of vitamin D in breast cancer biologically plausible. Preclinical and ecologic studies have suggested a role for vitamin D in breast cancer prevention. Inverse associations have also been shown between serum 25-hydroxyvitamin D level (25(OH)D) and breast cancer development, risk for breast cancer recurrence, and mortality in women with early-stage breast cancer. Clinical trials of vitamin D supplementation, however, have yielded inconsistent results. Regardless of whether or not vitamin D helps prevent breast cancer or its recurrence, vitamin D deficiency in the U.S. population is very common, and the adverse impact on bone health, a particular concern for breast cancer survivors, makes it important to understand vitamin D physiology and to recognize and treat vitamin D deficiency. In this review, we discuss vitamin D metabolism and its mechanism of action. We summarize the current evidence of the relationship between vitamin D and breast cancer, highlight ongoing research in this area, and discuss optimal dosing of vitamin D for breast cancer prevention.

Conflict of interest statement

Disclosures: Theresa Shao: None; Paula Klein: None; Michael L. Grossbard: None.

Figures

Figure 1.
Figure 1.
Vitamin D metabolism.

References

    1. Garland FC, Garland CF, Gorham ED, et al. Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation. Prev Med. 1990;19:614–622.
    1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281.
    1. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889–895.
    1. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res. 2003;164:29–42.
    1. Haddad JG, Jr, Rojanasathit S. Acute administration of 25-hydroxycholecalciferol in man. J Clin Endocrinol Metab. 1976;42:284–290.
    1. Looker AC, Pfeiffer CM, Lacher DA, et al. Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am J Clin Nutr. 2008;88:1519–1527.
    1. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72:690–693.
    1. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001;86:888–894.
    1. Welsh J. Targets of vitamin D receptor signaling in the mammary gland. J Bone Miner Res. 2007;22(suppl 2):V86–V90.
    1. Townsend K, Evans KN, Campbell MJ, et al. Biological actions of extra-renal 25-hydroxyvitamin D-1α-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol. 2005;97:103–109.
    1. Jensen SS, Madsen MW, Lukas J, et al. Inhibitory effects of 1α,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001;15:1370–1380.
    1. Simboli-Campbell M, Narvaez CJ, van Weelden K, et al. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat. 1997;42:31–41.
    1. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002;9:45–59.
    1. James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol. 1996;58:395–401.
    1. Ooi LL, Zhou H, Kalak R, et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res. 2010;70:1835–1844.
    1. Wang Q, Lee D, Sysounthone V, et al. 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat. 2001;67:157–168.
    1. Koli K, Keski-Oja J. 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ. 2000;11:221–229.
    1. Krishnan AV, Swami S, Peng L, et al. Tissue-selective regulation of aromatase expression by calcitriol: Implications for breast cancer therapy. Endocrinology. 2010;151:32–42.
    1. James SY, Mackay AG, Binderup L, et al. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol. 1994;141:555–563.
    1. Stoica A, Saceda M, Fakhro A, et al. Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem. 1999;75:640–651.
    1. Tangpricha V, Spina C, Yao M, et al. Vitamin D deficiency enhances the growth of MC-26 colon cancer xenografts in Balb/c mice. J Nutr. 2005;135:2350–2354.
    1. Welsh J. Vitamin D and breast cancer: Insights from animal models. Am J Clin Nutr. 2004;80(6 suppl):1721S–1724S.
    1. Narvaez CJ, Zinser G, Welsh J. Functions of 1α,25-dihydroxyvitamin D(3) in mammary gland: From normal development to breast cancer. Steroids. 2001;66:301–308.
    1. Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev. 2006;25:621–633.
    1. Wang D, Dubois RN. Cyclooxygenase-2: A potential target in breast cancer. Semin Oncol. 2004;31(suppl 3):64–73.
    1. Ristimäki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632–635.
    1. Boscoe FP, Schymura MJ. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer. 2006;6:264.
    1. Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer. 2002;94:272–281.
    1. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol. 1990;19:820–824.
    1. Porojnicu A, Robsahm TE, Berg JP, et al. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: A possible role of sun-induced Vitamin D. J Steroid Biochem Mol Biol. 2007;103:675–678.
    1. Porojnicu AC, Lagunova Z, Robsahm TE, et al. Changes in risk of death from breast cancer with season and latitude: Sun exposure and breast cancer survival in Norway. Breast Cancer Res Treat. 2007;102:323–328.
    1. Robsahm TE, Tretli S, Dahlback A, et al. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway) Cancer Causes Control. 2004;15:149–158.
    1. John EM, Schwartz GG, Dreon DM, et al. Vitamin D and breast cancer risk: The NHANES I Epidemiologic follow-up study, 1971–1975 to 1992. National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 1999;8:399–406.
    1. Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer. 2007;59:54–61.
    1. Knight JA, Lesosky M, Barnett H, et al. Vitamin D and reduced risk of breast cancer: A population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2007;16:422–429.
    1. Levi F, Pasche C, Lucchini F, et al. Dietary intake of selected micronutrients and breast-cancer risk. Int J Cancer. 2001;91:260–263.
    1. Potischman N, Swanson CA, Coates RJ, et al. Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancer. Int J Cancer. 1999;82:315–321.
    1. Rossi M, McLaughlin JK, Lagiou P, et al. Vitamin D intake and breast cancer risk: A case-control study in Italy. Ann Oncol. 2009;20:374–378.
    1. Simard A, Vobecky J, Vobecky JS. Vitamin D deficiency and cancer of the breast: An unprovocative ecological hypothesis. Can J Public Health. 1991;82:300–303.
    1. Decarli A, Franceschi S, Ferraroni M, et al. Validation of a food-frequency questionnaire to assess dietary intakes in cancer studies in Italy. Results for specific nutrients. Ann Epidemiol. 1996;6:110–118.
    1. Frazier AL, Li L, Cho E, et al. Adolescent diet and risk of breast cancer. Cancer Causes Control. 2004;15:73–82.
    1. Lin J, Manson JE, Lee IM, et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med. 2007;167:1050–1059.
    1. McCullough ML, Rodriguez C, Diver WR, et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2005;14:2898–2904.
    1. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: The Iowa Women's Health Study. Cancer Causes Control. 2007;18:775–782.
    1. Shin MH, Holmes MD, Hankinson SE, et al. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst. 2002;94:1301–1311.
    1. Xie SP, Pirianov G, Colston KW. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer. 1999;35:1717–1723.
    1. Colston KW, Perks CM, Xie SP, et al. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol. 1998;20:157–162.
    1. Xie SP, James SY, Colston KW. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol. 1997;154:495–504.
    1. Bezemer ID, Rinaldi S, Dossus L, et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: A cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC) Cancer Causes Control. 2005;16:561–572.
    1. Abbas S, Linseisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer—results of a large case-control study. Carcinogenesis. 2008;29:93–99.
    1. Abbas S, Chang-Claude J, Linseisen J. Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer. 2009;124:250–255.
    1. Bertone-Johnson ER. Prospective studies of dietary vitamin D and breast cancer: More questions raised than answered. Nutr Rev. 2007;65:459–466.
    1. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100:1581–1591.
    1. Crew KD, Gammon MD, Steck SE, et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2009;2:598–604.
    1. Engel P, Fagherazzi G, Boutten A, et al. Serum 25(OH) vitamin D and risk of breast cancer: A nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev. 2010;19:2341–2350.
    1. Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2008;17:889–894.
    1. Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41:1164–1169.
    1. Chen P, Hu P, Xie D, et al. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. 2010;121:469–477.
    1. Gammon MD, Neugut AI, Santella RM, et al. The Long Island Breast Cancer Study Project: Description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat. 2002;74:235–254.
    1. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: A cross-sectional study in healthy women. Eur J Endocrinol. 2004;150:161–171.
    1. Freedman DM, Looker AC, Chang SC, et al. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst. 2007;99:1594–1602.
    1. Goodwin PJ, Ennis M, Pritchard KI, et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27:3757–3763.
    1. Gerend MA, Pai M. Social determinants of Black-White disparities in breast cancer mortality: A review. Cancer Epidemiol Biomarkers Prev. 2008;17:2913–2923.
    1. Albain KS, Unger JM, Crowley JJ, et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009;101:984–992.
    1. Zadshir A, Tareen N, Pan D, et al. The prevalence of hypovitaminosis D among US adults: Data from the NHANES III. Ethn Dis. 2005;15(suppl 5):S5–97–S5–101.
    1. Steck SE, Rosling R, Murphy EA, et al. Vitamin D status and breast cancer aggressiveness among African women in South Carolina. Presented at the American Association for Cancer Research Conference; September 30 to October 3, 2010; Miami, FL.
    1. Guy M, Lowe LC, Bretherton-Watt D, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472–5481.
    1. Chen WY, Bertone-Johnson ER, Hunter DJ, et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2335–2339.
    1. Uitterlinden AG, Fang Y, van Meurs JB, et al. Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states. J Steroid Biochem Mol Biol. 2004;89–90:187–193.
    1. Buyru N, Tezol A, Yosunkaya-Fenerci E, et al. Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med. 2003;35:550–555.
    1. Bretherton-Watt D, Given-Wilson R, Mansi JL, et al. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer. 2001;85:171–175.
    1. Hou MF, Tien YC, Lin GT, et al. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat. 2002;74:1–7.
    1. Ingles SA, Garcia DG, Wang W, et al. Vitamin D receptor genotype and breast cancer in Latinas (United States) Cancer Causes Control. 2000;11:25–30.
    1. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet. 2010;376:180–188.
    1. Abbas S, Linseisen J, Slanger T, et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev. 2008;17:1339–1343.
    1. McCullough ML, Stevens VL, Diver WR, et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: A nested case-control study. Breast Cancer Res. 2007;9:R9.
    1. Prentice RL, Anderson GL. The women's health initiative: Lessons learned. Annu Rev Public Health. 2008;29:131–150.
    1. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr. 2007;85:1586–1591.
    1. Refice SF, Hershman DL, Maurer MA, et al. Safety of high-dose vitamin D supplementation in premenopausal women at high risk for breast cancer. Presented at the 33rd San Antonio Breast Cancer Symposium; December 8–12, 2010; San Antonio, TX.
    1. Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr. 2008;87:1087S–1091S.
    1. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90:3215–3224.
    1. Lips P, Chapuy MC, Dawson-Hughes B, et al. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int. 1999;9:394–397.
    1. Holick MF. 25-OH-vitamin D assays. J Clin Endocrinol Metab. 2005;90:3128–3129.
    1. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2003;921:1–164. back cover.
    1. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: Vitamin D recommendations for older adults. Osteoporos Int. 2010;21:1151–1154.
    1. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–58.
    1. Tangpricha V, Pearce EN, Chen TC, et al. Vitamin D insufficiency among free-living healthy young adults. Am J Med. 2002;112:659–662.
    1. Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004;158:531–537.
    1. Sullivan SS, Rosen CJ, Halteman WA, et al. Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc. 2005;105:971–974.
    1. Khan QJ, Reddy PS, Kimler BF, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2010;119:111–118.
    1. Friedman CF, DeMichele A, Su HI, et al. Vitamin D deficiency in post-menopausal breast cancer survivors. Presented at the 33rd Annual San Antonio Breast Cancer Symposium; December 8–12, 2010; San Antonio, TX.
    1. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr. 2003;22:142–146.
    1. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol. 2007;103:708–711.
    1. Caniggia A, Lorè F, di Cairano G, et al. Main endocrine modulators of vitamin D hydroxylases in human pathophysiology. J Steroid Biochem. 1987;27:815–824.
    1. Gilad LA, Bresler T, Gnainsky J, et al. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol. 2005;185:577–592.
    1. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93:677–681.
    1. Heaney RP, Davies KM, Chen TC, et al. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204–210.
    1. Holick MF, Chen TC. Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr. 2008;87:1080S–1086S.
    1. Chel V, Wijnhoven HA, Smit JH, et al. Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents. Osteoporos Int. 2008;19:663–671.
    1. Ish-Shalom S, Segal E, Salganik T, et al. Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab. 2008;93:3430–3435.
    1. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet. 1998;351:805–806.
    1. Crew KD, Shane E, Cremers S, et al. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol. 2009;27:2151–2156.
    1. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S–586S.
    1. Hathcock JN, Shao A, Vieth R, et al. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85:6–18.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する